β2-adrenergic receptor regulates ER-mitochondria contacts

Youngshin Lim1,2,4, Il-Taeg Cho1,3,4, Helmut G. Rennke1 & Ginam Cho1,2,*

Interactions between the endoplasmic reticulum (ER) and mitochondria (Mito) are crucial for many cellular functions, and their interaction levels change dynamically depending on the cellular environment. Little is known about how the interactions between these organelles are regulated within the cell. Here we screened a compound library to identify chemical modulators for ER-Mito contacts in HEK293T cells. Multiple agonists of G-protein coupled receptors (GPCRs), beta-adrenergic receptors (β-ARs) in particular, scored in this screen. Analyses in multiple orthogonal assays validated that β2-AR activation promotes physical and functional interactions between the two organelles. Furthermore, we have elucidated potential downstream effectors mediating β2-AR-induced ER-Mito contacts. Together our study identifies β2-AR signaling as an important regulatory pathway for ER-Mito coupling and highlights the role of these contacts in responding to physiological demands or stresses.

The membrane contacts between the ER and Mito are amongst the most extensively studied inter-organelle contacts1. In yeast, ER-Mito contact sites are primarily tethered by the ER-Mito encounter structure (ERMES) complex3,4. In mammalian cells, the molecular identities of such complexes are less clear and the precise role of candidates is still debated5. The functions of the ER-Mito contact sites include Ca2+ and lipid transfer, mitochondrial fusion/fusion control, autophagosome/mitophagosome biogenesis and apoptosis control6. The failure to maintain normal ER-Mito contacts is a common feature of neurodegenerative, cardiovascular, metabolic diseases, and cancer4–7. For example, the disease-associated mutations in receptor expression enhancing protein1 (REEP1), linked to hereditary spastic paraplegia, result in decreased ER-Mito contacts8.

Accumulating evidence suggests that both abnormal increases and decreases in these contacts are detrimental to normal cellular physiology4. If they are abnormally enhanced as in some Alzheimer’s disease models4, the resulting Mito Ca2+ overload can lead to the opening of Mito permeability transition pores (mPTP) and subsequently to cell death4. On the other hand, reduced or disrupted contacts, as in some models of amyotrophic lateral sclerosis (ALS)4, are predicted to lower Mito ATP generation4, which in turn is postulated to drive neuronal degeneration10. Despite the increasing evidence implicating ER-Mito contacts in the pathogenesis of many diseases and highlighting their importance in maintaining normal cellular physiology, little is known about how the contacts are regulated.

GPCRs are well known to sense various extracellular stimuli, ranging from photons and ions to growth factors and hormones11,12. They transduce signals through heterotrimeric G proteins that consist of α, β, and γ subunits. Upon activation, the α subunit (Gα), dissociated from the β/γ (Gβγ) subunits, elicits subtype (Gαs, Gαi, Gαq, and Gα12) specific downstream responses13. Thus, the G-protein coupling preference of GPCRs determine the downstream pathways they activate. For instance, β2-AR, mainly coupled to Gαs, activates the pathway that relays a signal to adenylyl cyclase (AC) to generate cAMP whose downstream effectors include PKA (protein kinase A) and EPAC (exchange protein directly activated by cAMP)13. Among the myriad of downstream events triggered by β-AR signaling, α-synuclein expression enhancement has been recently linked to an underlying drug mechanism of β2-AR agonists, drugs shown to be associated with decreased risk in Parkinson’s disease (PD) and beneficial in several PD models4,14. The role of β2-AR in ER-Mito contacts is unknown.

We previously developed a split- Renilla luciferase reconstitution assay (referred to as split-Rluc assay hereafter) to quantitatively measure the level of physical coupling between ER and Mito4,15. Using this assay, we screened a compound library for ER-Mito contact enhancers in HEK293T cells and identified several agonists of GPCRs, mostly β-ARs. We verify that β2-AR activation enhances physical as well as functional couplings between the two organelles. Uncovering the potential downstream effectors, our results provide novel insights

1Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA. 2Present address: Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 3Present address: Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. 4These authors contributed equally: Youngshin Lim and Il-Taeg Cho. 5email: ginam.cho@cshs.org
into how β2-ARs can modulate the ER-Mito coupling to elicit appropriate cellular responses. Furthermore, our successful compound screen demonstrates that the split-Rluc assay is an optimal, valid assay for screening, as it readily adapts to a high throughput detection in live cells without artifacts associated with fixation or complications related to image analysis.

Results

**GPCR agonists were identified in a compound library screen for ER-Mito contact enhancers.** We used the NIH Clinical Collection (NCC) library to screen for ER-Mito contact enhancers (Fig. 1). The HEK293T cells expressing split-Rluc constructs were treated with DMSO (control) or each drug (1 μM) (Fig. 1A,B), and the reconstituted split-Rluc activities (referred to as split-Rluc activities hereafter) in live cells were measured and normalized by the quantile method. From the initial screen, we identified 32 compounds (4.4% of the library) using the cut-off value of 3 standard deviation (SD) above the average of the control (Fig. 1C; Table S1). These compounds target GPCRs (18 drugs, 56% of the hits), glucocorticoid receptors (5 drugs, 16%; labeled as steroid), DNA topoisomerases/polymerases (5 drugs, 16%; labeled as DNA related), and others (3 drugs, 9%) (Fig. 1C–E; Table S1).

Given the high percentage (56%) of the GPCR-linked drugs among the compounds that scored in our screen, we selected the 18 GPCR-linked hits to test for the replication of the results. Repeated split-Rluc assay confirmed that 11 compounds showed consistent and significant increase in split-Rluc activity (Fig. 1F). Among these 11 compounds, nine were agonists of β-ARs while the other two, alprostadil (a.k.a. prostaglandin E1, PGE1) and 2-chloro-N6-cyclopentyladenosine (CCPA), target prostaglandin and adenosine receptors, respectively (Fig. 1G). Considering only 3% (10 of 331) of the GPCR-linked drugs and 1.4% (10 of 720) of the total drugs in this library were β-AR agonists (Fig. 1E,H; Table S2, S3), these data indicate an enrichment of β-AR agonists in our screen.

While 9 compounds are all β-AR agonists (epinephrine and norepinephrine activate both α- and β-ARs), α-AR agonists did not score as contact enhancers (Fig. 1H; Table S3), probably due to relatively low expression levels of α-ARs (TPM is less than 2 for ADRA1A, 1B, 1D and ADRA2A, 2B), except for ADRA2C (TPM 5.97), according to the available mRNA-seq data in HEK293T cells (Table S4).

Among the target GPCRs identified in screen, adenosine (ADORA1, 2A, 2B, and 3)- or prostaglandin (PTGER1-4)-receptors are expressed in low level or not detected in HEK293T cells (Table S4). In contrast, β2-AR (ADRB2) transcripts are relatively abundant, although β1- or β3-AR (ADRB1 or ADRB3) expression is low or not detected. Thus, we focused on a β-AR agonist isoproterenol (PubChem CID 3779), which acts on β1-and β2-ARs, for further analyses. Of note, HEK293T cells were used for all the following split-Rluc assays unless stated otherwise.

First, a dose response of the drug effect was examined by measuring the split-Rluc activity in HEK293T cells treated with different concentrations (25 nM to 5 μM) of isoproterenol. Increasing isoproterenol concentration increased the split-Rluc activity as shown in dose–response curve (Fig. S1A). Next, we tested the ability of a β-AR antagonist to counteract the drug effect of isoproterenol. A β-AR antagonist sotalol indeed abolished the split-Rluc activity induced by isoproterenol (1.00 ± 0.124, DMSO; 1.32 ± 0.102, isoprot; 1.08 ± 0.114, isoprot/sotalol) (Fig. S1B), confirming the drug activity of isoproterenol is specifically mediated through β-AR pathway. Given that β2-AR is a main β-AR receptor type expressed in HEK293T cells (Table S4), thus likely the responsible receptor for the biologic effect, we also evaluated the effect of a selective inverse β2-AR agonist, ICI 118551 hydrochloride. As expected, increasing ICI 118551 hydrochloride concentration decreased the split-Rluc activity (Fig. S1C), the opposite effect of isoproterenol, further supporting a specific involvement of β2-AR in ER-Mito contact regulation. Furthermore, we tested the cell line specificity of the drug effect using three additional cell lines, HeLa, C2C12, and Neuro2a cells. HeLa and C2C12 cells were responsive to isoproterenol like HEK293T cells, while Neuro2a cells were not (Fig S1D). This is likely due to the differences in receptor availability in these cell lines; Neuro2a cells have little or no β2-AR expression, while the other three cell lines express β2-ARs albeit weaker level in HeLa cells (Table S4). When Neuro2a cells were transfected with a construct expressing β2-AR, they became responsive to isoproterenol, while cells transfected with control vector did not (Fig S1E). Taken together, these data strongly support a specific role of β2-AR in isoproterenol-induced ER-Mito contacts.

Next, to address whether the agonist-induced split-Rluc activity results from enhanced transcription of the reporter constructs, we measured the effect of isoproterenol in the presence/absence of the transcription inhibitor actinomycin D (Act D) (Fig. S2A). In the cells treated with Act D alone, split-Rluc activity was lowered. However, isoproterenol treatment counteracted the inhibitory effect of Act D (Fig. S2A), supporting that the isoproterenol-induced split-Rluc activity results from the elevated physical coupling between the two organelles and not just from increased transcription alone. In fact, the expression level of the two split fragments (RlucC-ER and Mito-RlucN) were comparable between the vehicle- and isoproterenol-treated cells (Fig. S2B, C; S7). Our data also indicate that the half-life of each fragment is relatively short (approximately 3 h for Mito-RlucN; 5 h for RlucC-ER) (Fig. S2D, E; S8).

**Isoproterenol, β2-AR agonist, increases physical contacts between ER and mitochondria.** To corroborate our split-Rluc assay results and validate the drug effect on ER-Mito contacts, we employed three independent assays. First, a proximity ligase assay (PLA), which detects the proximity of the two proteins in the cell with specific primary antibodies and oligonucleotide-linked secondary antibodies, was performed in HeLa cells. Of note, HeLa cells were used in all PLA experiments in this study for their easiness to handle in imaging experiments (e.g., better adhesion to the plates and more copious cytoplasm) despite their weaker response to isoproterenol compared to HEK293T cells (Fig S1D, S5A), probably due to lower expression of ADRB2 according to the available mRNA-seq data (see Table S4). When SEC61 (ER protein) and TOM20 (mitochondrial protein) are in sufficient proximity, the interaction between these two proteins—i.e., membrane-membrane

...
Figure 1. Compound library screening with split-Rluc assay identifies GPCR agonists. (A) Schematic of split-Rluc assay. (B) Schematic of screen workflow. (C) Initial screen results depicted with circular packaging dendrogram (each circle: each drug; circle size: normalized drug activity). Green to yellow circles indicate 32 hits. (D) Dendrogram of 32 initial hits. Circle size: normalized drug activity. Numbers in the parenthesis: false discovery rate (adjusted p values). (E) Circular dendrogram of all GPCR-associated drugs grouped into each pathway (Drug IDs with orange color: 18 hits). (F) Repeated split-Rluc assay in HEK293T cells treated with 11 hits targeting GPCRs. RLU (relative light unit): normalized luciferase activity (to the mean of DMSO). n = 3 experiments; 1-way ANOVA with Dunnett’s multiple comparisons test; *p = 0.0135; ****p < 0.0001. (G) List of 11 confirmed hits targeting GPCRs. AR adrenergic receptor, AdR adenosine receptor, CCPA 2-chloro-N’cyclopentyladenosine, PGE1 prostaglandin E1, PGE2R PGE2 receptor. (H) Circular dendrogram of all AR-associated drugs grouped based on target specificity. Circle size: normalized drug activity; circle color: target specificity; red curve with asterisk (*): 9 hits targeting ARs.
apposition between ER and Mito—generates a fluorescent product (red) that can be detected in situ (Fig. 2A). Isoproterenol-treated cells showed significant increase in PLA fluorescent signal, demonstrating that this drug indeed facilitates ER-Mito contacts (Fig. 2A,B). Of note, different treatment time of isoproterenol resulted in different level of responses in PLA signal (Fig. S3C), suggesting a dynamic nature of the drug effect on ER-Mito contacts. When PLA was performed in HeLa cells treated with CCPA (PubChem CID 123807; adenosine A1 receptor agonist) or PGE (PubChem CID 5280723; prostaglandin E2 receptor agonist), both of which were iden-
Cells was significantly higher (DMSO, 22.5%; isoproterenol, 41.7%; \( p < 0.0001 \); Chi-square test) (Fig. 2C, D). Furthermore, the isoproterenol-treated cells showed a significant increase in total contact coverage, calculated as the percent of the total contact length divided by the total Mito perimeter measured among all mitochondria (5.6 ± 2.1%, control; 14.6 ± 2.7%, isoprot; \( p = 0.0286 \)) (Fig. 2E). Interestingly, when only the mitochondria having a tight coupling with ER were compared, the percent of contact length did not show a statistically significant difference (Fig. 2F). We speculate that isoproterenol might increase the proximity of the ER and Mito (contact width) or the number of contacts, with little or no effect on contact length.

Finally, the ascorbate peroxidase (APEX)-proximity labeling method was employed, which biotinylates proteins within 20 nm proximity of the enzyme. Mito-APEX, targeted to Mito outer membrane, can label and identify ER proteins in close proximity to the Mito26. HEK293T cells transfected with mito-APEX were treated with DMSO or isoproterenol, and the biotinylated proteins (by incubating with biotin-phenol and with \( \text{H}_{2}\text{O}_{2} \)) were affinity-purified using streptavidin-magnetic beads and subjected to Western blot analysis. In these affinity-purified samples (which were within 20 nm proximity to the Mito membrane) prepared from the isoproterenol-treated cells, we found that ER proteins IP3R1 and SEC61b were increased, but not cytosolic protein GAPDH.

Isoproterenol facilitates mitochondrial Ca\(^{2+}\) uptake and bioenergetics. We next investigated if drug-induced physical contacts created functional coupling between the ER and Mito. Given the role of ER-Mito contact sites as hotspots for Ca\(^{2+}\) influx to mitochondria (Mito)21–23, we explored if agonist treatment increases Mito Ca\(^{2+}\) influx, using a fluorescent Ca\(^{2+}\) sensor mito-R-GECO118. HeLa cells were pre-treated with DMSO or isoproterenol, and then the Mito Ca\(^{2+}\) uptake was measured every 2.5 s in response to histamine-stimulated ER Ca\(^{2+}\) release (Fig. 3A). Upon ER Ca\(^{2+}\) release, isoproterenol elevated Mito Ca\(^{2+}\) uptake (Fig. 3A), resulting in a higher maximum peak (Fig. 3B) and faster uptake rate (Fig. 3C). Also, when ionomycin (Ca\(^{2+}\) ionophore) was used to trigger cytoplasmic Ca\(^{2+}\) influx, a similar increase in Mito Ca\(^{2+}\) uptake was observed (Fig. 3D). Together these data support that the \( \beta_{2} \)-AR agonist isoproterenol enhances physical contacts between the ER and Mito.

G\(_{\alpha_s}\)/CAMP mediates \( \beta_{2} \)-AR signal-induced ER-Mito contacts. To gain insight into the downstream factors of the \( \beta_{2} \)-AR signaling involved in ER-Mito contact modulation, we evaluated the involvement of the G\(_{\alpha_s}\) pathway because G\(_{\alpha_s}\) is the primary G\(_{\alpha}\) coupled to \( \beta_{2} \)-AR (Fig. 4A)23. First, we examined the G\(_{\alpha_s}\) pathway activation using a cAMP response element (CRE) reporter gene assay (a proxy for cAMP measurement). Compared to DMSO, isoproterenol increased CRE reporter activity in HEK293T cells (fold change: 4.79 ± 1.66) (Fig. S5A), confirming G\(_{\alpha_s}\) pathway activation by isoproterenol. A similar result was observed in HeLa cells with a lower increase in CRE reporter activity (Fig. S5A). When \( \beta_{2} \)-AR itself was overexpressed, it induced much higher CRE reporter activity (fold change: 249.60 ± 19.90) (Fig. S5B) than isoproterenol treatment, arguing that the isoproterenol-mediated \( \beta_{2} \)-AR stimulation in our assay is not as strong as a full activation via receptor overexpression, as expected.

Next, we asked if G\(_{\alpha_s}\) pathway activation influences the level of ER-Mito contacts. A constitutively active construct for G\(_{\alpha_s}\) (G\(_{\alpha_s}\) CA), which activates the signaling cascade even in the absence of ligand24, augmented split-Rluc activity (Fig. 4B). Corroborating these results, an adenylyl cyclase (AC) activator forskolin (thus increasing cAMP level) enhanced PLA signal (Fig. 4E). Together these results demonstrate that G\(_{\alpha_s}\)/AC/cAMP pathway activation leads to an increase in ER-Mito contacts.

Because CAMP can transduce signal through two different downstream effectors, EPAC and PKA, we next examined which of these factors were involved in mediating the signal for contact regulation. Using two different tools, a dominant negative (DN) construct and a pharmacological inhibitor (ESI 09), we determined if EPAC activity is required for G\(_{\alpha_s}\)/AC/cAMP pathway-induced contacts. The EPAC DN construct significantly reduced G\(_{\alpha_s}\) CA-induced split-Rluc activity (fold change: 3.49 ± 0.164, G\(_{\alpha_s}\) CA; 2.28 ± 0.074, G\(_{\alpha_s}\) CA/EPAC DN; \( p < 0.0001 \)) without affecting basal level of split-Rluc activity (fold change: 1.00 ± 0.069, pCIG (vector); 0.97 ± 0.035, EPAC DN). Similarly, a chemical inhibitor of EPAC, ESI 09, caused a significant reduction in isoproterenol-induced split-Rluc activity (Fig. 4C, left). Because it also reduced the split-Rluc activity in DMSO-treated cells (Fig. 4C, left), we compared the fold changes of the isoproterenol-induced activity (over DMSO)
Figure 3. β2-AR agonists enhance functional coupling between ER and Mito. (A) Mito Ca\(^{2+}\) uptake in response to histamine (100 μM). Mito-R-GECO1 fluorescent intensity change averaged over multiple cells (HeLa) is plotted every 2.5 s in DMSO- or isoproterenol- treated cells. Arrow: histamine addition. (B) Maximum peak of Mito Ca\(^{2+}\) uptake (as in A). Unpaired two-tailed t-test (n = 10, DMOS; 14, Isoprot). (C) Mito Ca\(^{2+}\) uptake rate (as in A; 7.5 to 12.5 s). Mann–Whitney test (n = 12, DMSO; 11, Isoprot). (D) Mito Ca\(^{2+}\) uptake (HeLa cells) in response to ionomycin (3 μM). Mito-R-GECO1 fluorescent intensity change is plotted every 5 s. (E) Representative images of TMRM signal (for Mito membrane potential) (HeLa cells). (F) Quantification of TMRM intensity as in E. Unpaired two-tailed t-test with Welch’s correction (n = 4 with 52 cells each). (G) Representative images of Mito (converted in Image Analyst MKII software) used for length comparison (HeLa cells, 1 μM drug). (H) Quantification of Mito length as in (G). Mann Whitney test (n = 4 with 616 (DMSO) or 948 (Isoprot) mitochondria for each experiment). Each drug: used at 1 μM final conc. Data in (B,C): mean ± SD; data in (F,H): median with interquartile range. Scale bars: 10 μm.
between the vehicle- vs. ESI 09- treated cells and found a statistically significant difference (1.54 ± 0.128, vehicle; 1.19 ± 0.057, ESI 09; p < 0.0001) (Fig. 4C, right). Together with EPAC DN data, these results confirm the requirement of the EPAC for the isoproterenol-induced contacts, although ESI-09 appears to affect basal level contacts as well. Corroborating these results, the PLA in HeLa cells also demonstrated a similar inhibitory effect of ESI 09 (Fig. 4D). Consistent with these data, ESI 09 also blocked forskolin-induced PLA signal enhancement (forskolin increases cAMP by stimulating adenylyl cyclase) (Fig. 4E). Of note, we found that RAP1A (EPAC downstream effector) is also involved, as RAP1A DN decreased the isoproterenol response (Fig. 4F), albeit its effect is not
Elevated cytosolic Ca$^{2+}$ participates in β-AR signal-induced ER-Mito contacts. In addition to cAMP, cytosolic Ca$^{2+}$ level is also known to increase upon β-AR activation by isoproterenol (Fig. 5A). We thus set out to evaluate the potential role of cytosolic Ca$^{2+}$ in isoproterenol-induced ER-Mito interactions. First, we ensured an increase in cytoplasmic Ca$^{2+}$ level upon isoproterenol application to the cells by using fluorescent Ca$^{2+}$ sensor GCaMP6s (Fig. 5B). Next, we investigated if intracellular Ca$^{2+}$ increase itself could enhance ER-Mito interactions. For this, we assessed the effects of the three different drugs, histamine, ionomycin and cyclopiazonic acid (CPA), all of which are known to elevate cytosolic Ca$^{2+}$ albeit by distinct mechanisms. Histamine stimulates cytosolic Ca$^{2+}$ release from the ER through IP3 receptor activation; ionomycin, a membrane permeable Ca$^{2+}$ ionophore, allows both Ca$^{2+}$ release from intracellular stores and extracellular Ca$^{2+}$ influx to the cytoplasm; and CPA, a sarco-endoplasmic reticulum Ca$^{2+}$-ATPase (SERCA) inhibitor, blocks the uptake of Ca$^{2+}$ ions back to the sarcoplasmic reticulum (SR)/ER lumen after their release into the cytosol, thus accumulating Ca$^{2+}$ in the cytoplasm. All three drugs elevated Split-Rluc activity (Fig. 5C), suggesting that increasing cytosolic Ca$^{2+}$ concentration is sufficient to enhance ER-Mito contacts. We corroborated these findings with the PLA results; histamine or ionomycin treatment increased PLA signal (Fig. 5D).

Finally, we examined if cytoplasmic Ca$^{2+}$ increase is required for isoproterenol-induced ER-Mito coupling. A recently identified calcium mobilization inhibitor, ebselen, eliminated the positive effect of isoproterenol (Fig. 5E), proving the requirement of cytosolic Ca$^{2+}$ in isoproterenol-induced contacts. However, considering its multiple inhibitory functions, the possibility of ebselen inhibiting other factors or pathways could not be excluded. Unlike ebselen, the PLC inhibitors edelfosine and U73122 exhibited a rather mild inhibition on isoproterenol-induced ER-Mito contacts (Fig. 5EG). When the fold changes of the isoproterenol-induced luciferase activity (over DMSO) were compared between the vehicle- vs. each drug- treated cells, edelfosine showed a trend toward blocking isoproterenol response (p = 0.0674) although the effects of both drugs did not reach statistical significance (Fig. 5FG; right). These data argue for a significant involvement of Ca$^{2+}$ but a negligible role of PLC in β-AR signaling-induced ER-Mito coupling.

Actin polymerization is required for β-AR signal-mediated ER-Mito contact regulation. Finally, we explored the potential mechanism by which cytosolic Ca$^{2+}$ and cAMP could modulate ER-Mito interaction. It has been shown that cytosolic Ca$^{2+}$ spike by multiple stimuli such as ionomycin and histamine, triggers a transient surge in cytosolic actin polymerization, which is required for ER-Mito contacts. Thus, we postulated that an actin polymerization (regulated by cytosolic Ca$^{2+}$ rise and cAMP upon β-AR activation) would be required for isoproterenol-induced ER-Mito interaction. To test this hypothesis, the cells were treated with latrunculin A, an actin polymerization inhibitor, and its effect on isoproterenol activity was assessed. Supporting our hypothesis, latrunculin abolished the isoproterenol-induced split-Rluc activity (Fig. 6B). This finding supports a model that actin filament assembly triggered by β-AR activation may facilitate a close contact between the ER and Mito.

In the cell, actin reorganization is mainly regulated by RHO GTPases; CDC42, RAC, and RHO are the most prominent members among them (Fig. 6A). It has been well established that the activation of CDC42, RAC, and RHO promotes actin polymerization (Fig. 6A). These RHO GTPases are regulated by GEFs (guanine nucleotide exchange factors), GAPs (GTase activating proteins) and GDIs (guanine nucleotide dissociation inhibitors); the GPCR signaling is linked to the activation of these regulators. In addition to G$_{12}$ mediated pathway which is well documented for regulating RHO GTPases through RHO GEFs, increased intracellular Ca$^{2+}$ (via activating calmodulin) as well as cAMP (via activating EPAC) play roles in activating RHO GTPases. This prompted us to test if CDC42, RAC, and RHO participate in β-AR-induced ER-Mito contact formation.

To address this, CDC42, RAC, or RHO activity was pharmacologically inhibited in the presence of isoproterenol and then ER-Mito contacts were assayed. The CDC42 inhibitor ZCL 278 completely eradicated the effect of isoproterenol (Fig. 6C), supporting a role for CDC42 in β-AR-induced ER-Mito contacts, likely by triggering actin polymerization. This result was corroborated by PLA results where ZCL 278 counteracted the positive effect of forskolin on ER-Mito contacts (Fig. 4E). The RAC inhibitor EH016 also reduced split-Rluc activity when treated with or without isoproterenol (Fig. 6D, left). However, its inhibitory effect appeared to be independent of isoproterenol response, considering that the fold increase by isoproterenol over DMSO was in fact higher in EH016-treated cells when compared to vehicle-treated ones (Fig. 6D, right). Finally, when RHO activity was inhibited by rhosin, no changes in isoproterenol response was detected (Fig. 6E). These results strongly support that actin polymerization triggered by CDC42, but not by RAC or RHO, is a downstream event facilitating ER-Mito coupling, in response to β-AR signal.

Of note, another cytoskeletal drug nocodazole, which interferes microtubule polymerization and blocks mitochondrial motility, caused a dose-dependent increase in split-Rluc activity; this suggests that microtubule polymerization normally hinders ER-Mito contacts probably due to excess mitochondrial dynamics along the microtubule (Fig. SSD; see "Discussion"). Together these results implicate an important role of cytoskeletal dynamics in ER-Mito contact modulation.
Figure 5. Cytoplasmic Ca\(^{2+}\) participates in β2-AR signal-induced ER-Mito contact. (A) Schematic of the simplified β-AR pathway leading to cytosolic calcium increase. Chemical inhibitors: red. Asterisk (*) : drugs with negligible effect on isoproterenol-induced ER-Mito coupling. IP3 inositol triphosphate, PLC phospholipase C, GEFs Guanine nucleotide exchange factors; (B) Cytoplasmic Ca\(^{2+}\) level measured by GCaMPs fluorescence intensity fold change (ΔF/F₀) in HeLa cells treated with DMSO or isoprot (1 μM) every 2.5 s (averaged over 16 cells). (C) Split-Rluc activities in DMSO, histamine (100 μM), ionomycin (1 μM), or CPA (10 μM) treated HEK293T cells. 1-way ANOVA with Dunn’s multiple comparisons test (left; n = 6); two-tailed t-test (right, n = 9). (D) Quantification of PLA in HeLa cells (n = 4 with 66, 57, 97, 87 cells for DMSO, histamine, DMSO, ionomycin; Mann Whitney test). (E–G) (Left) Split-Rluc assay in HEK293T cells treated with vehicle or indicated drugs (ebselen, 50 μM; edelfosine, 40 μM; or U73122, 5 μM), in the presence of DMSO or isoproterenol (1 μM). n = 8; 2-way ANOVA with Sidak’s multiple comparisons test. (Right) Fold change of isoproterenol-induced luciferase activity (isoprot/DMSO) in the presence of vehicle vs. indicated drugs (using the same data sets from the left graphs in E–G); two-tailed t-test. All data except in D: mean ± SD; data in D: median with interquartile range.
Discussion

Communication between the ER and Mito via membrane contact sites is crucial for many cellular functions. Although recent studies have focused on identifying the molecular components of the contacts, the signaling pathway(s) involved in contact regulation remains unknown. Herein we have identified β2-AR signaling as a significant pathway modulating ER-Mito contact modulation. Drugs with red color: the ones blocking isoprot-induced split-Rluc activity; with black color, not blocking. (B–D) (Left): Split-Rluc assay in HEK293T cells treated with vehicle or indicated drugs (Latrunculin, 1 μM; ZCL 278, 25 μM; EHop 016, 12.5 μM) in the presence of DMSO or isoprot (1 μM). Fold changes: normalized to the mean of DMSO/vehicle. n = 8 (B), 16 (C), 8 (D); 2-way ANOVA with Sidak’s multiple comparisons test. (Right): Fold change of isoprot-induced luciferase activity (isoprot/DMSO) in the presence of vehicle vs. indicated drugs (same data from the left graphs in B–D). Two-tailed t-test. (E) Split-Rluc assay in HEK293T cells treated with vehicle or Rhosin (25 μM) in the presence of DMSO or isoprot (1 μM). Fold changes: normalized to the mean of DMSO/vehicle. n = 8; 2-way ANOVA with Sidak’s multiple comparisons test. All data: mean ± SD.

Figure 6. Actin polymerization is required for isoproterenol-induced ER-Mito contact regulation. (A) A schematic diagram (simplified) displaying the Rho GTPases and their upstream regulators potentially involved in actin polymerization. Arrow: pathways potentially involved (black) or not-involved (grey) in β-AR-mediated ER-Mito contact modulation. Drugs with red color: the ones blocking isoprot-induced split-Rluc activity; with black color, not blocking. (B–D) (Left): Split-Rluc assay in HEK293T cells treated with vehicle or indicated drugs (Latrunculin, 1 μM; ZCL 278, 25 μM; EHop 016, 12.5 μM) in the presence of DMSO or isoprot (1 μM). Fold changes: normalized to the mean of DMSO/vehicle. n = 8 (B), 16 (C), 8 (D); 2-way ANOVA with Sidak’s multiple comparisons test. (Right): Fold change of isoprot-induced luciferase activity (isoprot/DMSO) in the presence of vehicle vs. indicated drugs (same data from the left graphs in B–D). Two-tailed t-test. (E) Split-Rluc assay in HEK293T cells treated with vehicle or Rhosin (25 μM) in the presence of DMSO or isoprot (1 μM). Fold changes: normalized to the mean of DMSO/vehicle. n = 8; 2-way ANOVA with Sidak’s multiple comparisons test. All data: mean ± SD.

Our data support a model where EPAC activation via Gαs/AC/cAMP, and cytosolic Ca²⁺ increase lead to CDC42 activation and subsequently to actin filament assembly, a driving force for ER-Mito interaction (Fig. 7). In addition to CDC42, ER-bound inverted formin2 (INF2), could be a good candidate protein mediating actin polymerization in response to cytosolic Ca²⁺ burst upon GPCR activation. Furthermore, INF2-mediated actin polymerization at the ER increases ER-Mito contacts,
Mito Ca\(^{2+}\) uptake, and mitochondrial fission\(^{28}\), all of which were also increased with isoproterenol treatment (Figs. 2, 3).

In addition to stimulating actin dynamics, cAMP and cytosolic Ca\(^{2+}\) surge may also exert their effects through other mechanisms. For instance, they might facilitate the formation of ER-Mito coupling complexes. In fact, a recent study demonstrated that under stress condition, EPAC (activated by cAMP) enhances ER-Mito coupling by influencing actin polymerization through CDC42 or potentially through INF2 (inverted formin2) (ref.\(^{29}\)). It is also plausible that cAMP and Ca\(^{2+}\) might employ other mechanisms (e.g., Mito movement arrest on microtubule by Ca\(^{2+}\)) and that another downstream pathway of \(\beta\)2-AR might also participate in ER-Mito coupling. \(\beta\)2-AR-mediated ER-Mito coupling increases mitochondrial Ca\(^{2+}\) uptake, which enhances mitochondrial bioenergetics by activating proteins involved in TCA cycle and oxidative phosphorylation (OXPHOS).

**Figure 7.** Proposed model for potential mechanisms of \(\beta\)2-AR (GPCR) signaling in ER-Mito contact regulation. We postulate that the increase in cAMP and subsequent activation of EPAC facilitates ER-Mito interactions likely through (1) triggering actin polymerization by CDC42; (2) inducing tethering complex formation (e.g., VDAC1/IP3R1/GRP75). Increased cytosolic Ca\(^{2+}\) can also increase ER-Mito interactions by influencing actin polymerization through CDC42 or potentially through INF2 (inverted formin2) (ref.\(^{29}\)). It is also plausible that cAMP and Ca\(^{2+}\) might employ other mechanisms (e.g., Mito movement arrest on microtubule by Ca\(^{2+}\)) and that another downstream pathway of \(\beta\)2-AR might also participate in ER-Mito coupling. \(\beta\)2-AR-mediated ER-Mito coupling increases mitochondrial Ca\(^{2+}\) uptake, which enhances mitochondrial bioenergetics by activating proteins involved in TCA cycle and oxidative phosphorylation (OXPHOS).
likelihood of its interaction with ER. Consistent with this, nocodazole (an inhibitor of microtubule polymerization shown to block mitochondrial motility) increased ER-Mito contacts in a dose dependent manner (Fig. S5D).

Accumulating evidence indicates that ER-Mito dysfunction contributes to a variety of neurodegenerative diseases. In Parkinson’s disease models, β2-AR agonists have been documented to be beneficial. Salbutamol and metaproterenol (β2-AR agonists), both of which were also identified in our screen, reduce α-syn transcription levels and appears to reduce risk of developing PD. Although their efficacy was linked to α-syn transcription regulation and anti-inflammation, our data indicate that these drugs might also exert therapeutic effects by increasing ER-Mito contacts since some PD-associated mutation insults disrupt these contacts. This opens up the possibilities for therapy of other conditions associated with ER-Mito contact dysregulation. When considering ER-Mito contact enhancement drugs for therapeutic options, it is important to recognize that both increased and decreased contacts can be detrimental. Therefore, careful titration of these drugs will be crucial.

Analysis of our screen results suggest that the reason why β2-AR agonists, among other GPCR targeting drugs, were identified as the major modulators for the ER-Mito contacts, is probably because β2-AR is one of the most prominently expressed GPCRs in H293T cells used in our drug screen (see Table S4). Given that Gαs CA expression itself, as well as ionomycin or CPA treatment, elevated ER-Mito contacts (Figs. 4B, 5C), it is likely that any GPCRs that can trigger cAMP- or cytosolic Ca2+-increase may be able to modulate ER-Mito coupling. The implication that a broad range of GPCRs may be able to regulate ER-Mito contact is that the contact dynamics would be cell-type specific, because different cells will respond differently to the same stress/stimuli depending on their specific GPCR availability. Furthermore, considering the role of GPCRs in sensing various extracellular signals and subsequently eliciting appropriate cellular responses, our data provide strong evidence for the involvement of ER-Mito contacts in the adaptation of the cells to acute physiological conditions (e.g., starvation, high stress, etc.).

Our results also demonstrate that the split-Rluc assay can serve as a valid assay to screen for modulators of ER-Mito contacts, yet we recognize its limitation. Given that it takes approximately 1.5 h for EnduRen substrate to generate stable luminescence, which then will last for 24 h, the split-Rluc assay is not suitable to detect real-time dynamics of ER-Mito contacts. This explains the discrepancy between the PLA and split-Rluc assay when comparing the signal intensities in time course experiments for isoproterenol treatment; PLA signal shows increase (up to 3 h) then decrease (at 6 h) (Fig. S3C) probably due to negative feedback in GPCR signaling, while the split-Rluc activity shows continuous increase up to 16 h (maximum time measured) (data not shown). The split-Rluc assay appears to detect accumulated changes (irreversible), despite the relatively short half-life of each split fragment (Fig. S2D, E).

While our current screen focused on an FDA-approved drug library, further screens with other compound libraries will likely provide additional biologic insights into this important inter-organelle communication (e.g., identifying small molecules that could directly target ER-Mito contact sites). Furthermore, ORF or siRNA library screens would be warranted to identify additional molecular machinery functioning for the contact modulation. Finally, while our current screening system is most suitable for enhancer identification due to low basal level of split-Rluc activity, modification to our system could permit the screening for inhibitors in future studies. Furthermore, the detailed mechanisms of the GPCR pathway-regulated ER-Mito contacts and any distinctions, among different classes of GPCRs, in downstream pathways leading to ER-Mito contact modulation will need to be addressed.

Materials and methods

Plasmids and DNA constructs. Split-Rluc constructs (Mito-RlucN and RlucC-ER) have been described previously. R-GECO1 (plasmid #46021), GCaMP6s (plasmid #100848), and Sec61 β (plasmid #15108) were obtained from Addgene (gift from Robert Campbell, Douglas Kim & GENIE Project, and Tom Rapoport, respectively). CRE-luc2P (pGL4.29) used for CRE reporter gene assay was purchased from Promega. Plasmids expressing Gs CA (Q227L), Gq CA (Q209L), Gi CA (Q205L), RAP1A DN (S17N), and EPAC2 DN (R432K) were generated by cloning PCR-amplified cDNA fragments into pCAG-IRES-GFP (pCIG) vector (EcoRI/MluI). For the plasmid encoding β2-AR was generated by cloning PCR-amplified cDNA fragment into pCDH-EF1a-MCS-PGK-puro vector (EcoRI/NotI). For these cloning, HEK293T cDNAs, as a template, and specific primer sets including the ones containing mutations (see Table S5 for primer sequences) were used for PCR.

Compounds and chemical reagents. We used NIH Clinical Collections 1 and 2 (NCC) (Evotec, San Francisco, CA) containing 720 FDA approved drugs dissolved in 100% DMSO at a concentration of 10 mM (the original list contains 727 drugs; 7 of them duplicated). All drugs were used at 1 μM final concentration. The target pathway(s) of the members of this collection was manually curated from the information available in the PubChem portal (http://pubchem.ncbi.nlm.nih.gov/). For post-screen experiments, the chemical reagents were used as following: isoproterenol (1747, Tocris, 1 μM), sotalol (0952, Tocris, 250 μM), LCI 118,551 hydrochloride (0821, Tocris, 0.1–100 μM), actinomycin D (A9415, Sigma-Aldrich, 0.8 μM), cycloheximide (asd, 20 μg/ml), CCPA (119,136, Sigma-Aldrich, 1 μM), prostaglandin E1 (P5515, Sigma-Aldrich, 1 μM), ESI 09 (4773, Tocris, 5 μM), CAMPS-Rp (13,371, Tocris, 10 μM), H89 (2910, Tocris, 10 μM), PD0325901 (04–0006, Reprocell, 1 μM), histamine (H7250, Sigma-Aldrich, 100 μM), ionomycin (1704, Tocris, 1 μM), and cyclopiazonic acid (CPA) (C1530, Sigma-Aldrich, 10 μM), thapsigargin (T9033, Sigma-Aldrich, 0.1–10 μM), ebselen (5245, Tocris, 5 μM), edelfosine (3022, Tocris, 40 μM), U73122 (1268, Tocris, 5 μM), latrunculin (ab144290, Abcam, 1 μM), ZC278 (4794, Tocris, 25 μM), ELH016 (6248, Tocris, 12.5 μM), rosin (5003, Tocris, 25 μM), and nocodazole (S2775, Selleck Chemicals, 1, 4, and 10 ng/ml). For DMSO used as controls, the final concentration was decided according to the experimental drug’s final concentration (e.g., 0.01% DMSO was used as a control, when other drugs (in 100% DMSO) were used: 1:10,000 dilution).
**Cell culture and transfection.** HEK293T (ATCC, CRL-3216), HeLa (ATCC, CCL-2), C2C12 (ATCC, CRL-1773), and Neuro2a (ATCC) cells were maintained in DMEM (Thermo Fisher Scientific) with 10% (HEK293T, HeLa, Neuro2a) or 15% (C2C12) FBS (Thermo Fisher Scientific) in a humidified incubator at 37 °C with 5% CO2. For transfection in 8-well chamber slides, 12-well plates, and 100 mm culture dishes, cells were plated at a density of 3 x 10^5/well, 4 x 10^5/well, and 5 x 10^5/well respectively to obtain 75–80% confluency, and 100 ng, 400 ng, and 5 μg each of DNA constructs respectively were used with polyethylenimine (PEI; Polysciences, Eppelheim, Germany) as previously described.9 Of note, we have used different batches of HEK293T cells for the initial screen vs the subsequent experiments.

**Split-Renilla luciferase (split-Rluc) reconstitution assay.** HEK293T cells were used for all split-Rluc assays in this study unless otherwise mentioned, otherwise, a transient transfection of the split-Rluc reporter plasmids (Mito-RlucC and RlucC-ER) in 12 well plates. Four to six hours after transfection, cells were dissociated and re-plated into a 96-well plate coated with poly-D-lysine (50 μg/mL). Twenty-four hours post-transfection, live cell substrate EnduRen (30 μM, Promega) was added to the culture media and incubated for 2–5 h. Luciferase activity (luminescence) was measured by a POLARstar Omega microplate reader (BMG LABTECH, Ortenberg, Germany) and normalized to the mean of the control.

**Library screen.** HEK293T cells were transfected with split-Rluc constructs in a 100 mm dish and used for split-Rluc assay. 1 μM of each compound (final concentration) was added to each well together with Enduren and incubated for 5 h followed by luminescence measurement. The initial screen was carried out once. The split-Rluc activity of each drug was normalized by quantile normalization using R software (version 4.0). Hits were picked using the cut-off value of 3SD higher than the average of the control (DMSO), and further tested for their activity with one more round of split-Rluc assay. For drug enrichment analysis, we employed the over representation analysis.31 False discovery rate (FDR) was calculated by R software. All dendrograms were created using R with packages ‘ggraph’, ‘igraph’, ‘tidyverse’ and ‘RcolorBrewer’.

**Proximity labeling assay (PLA).** HeLa cells were used for all PLA experiments in this study. They were transfected with SEC61-GFP expression vector in 8 well chamber slide (Millpore Sigma, Millicell EZ SLIDE) and, 16 h after transfection, treated with DMSO or indicated drugs for 5 h. PLA was performed according to the manufacturer's recommendation (Duolink® In Situ Red Starter Kit Mouse/Rabbit, Sigma-Aldrich). Primary antibodies against GFP (ab13970, chicken polyclonal, Abcam) and Tom20 (sc-17764, mouse monoclonal, Santa Cruz Biotechnology) were used at 1:500 dilution each. After mounting, the images were captured by Zeiss Observer Z1 inverted microscope (Hamamatsu ORCA-Flash4.0 camera) using Zeiss Zen Pro software and analyzed in ImageJ with Maxima function. For analyses, all PLA studies were internally compared.

**Transmission electron microscopy (TEM).** HEK293T cells cultured in 100 mm dish were treated with DMSO or isoproterenol for 30 min. These monolayers of cells were fixed with glutaraldehyde/paraformaldehyde mixture and post-fixed in 2% aqueous OsO4 in 0.2 M S-collidine buffer, pH 7.4. One-micron thick sections were cut on an ultra-microtome and stained on the glass slide, and thin sections were mounted on 200 mesh copper grids. Transmission electron microscopy (TEM) was used with a slight modification. Briefly, cells were treated with DMSO or isoproterenol (1 μM) for 1 h, before incubated with biotin-phenol (500 μM) and treated with H2O2 for 3 min. After the biotinylation reaction was quenched, cells were lysed with RIPA buffer and centrifuged at 13,000 rpm for 10 min at 4 °C. To get rid of the free biotin-phenol, the sample was applied to Zeba Spin Desalting Column (Thermo Fisher Scientific). The recovered lysates were incubated with streptavidin magnetic beads and, the beads were washed five times with RIPA buffer. Biotinylated proteins of mito-APEX pull downs were eluted by boiling with 2X protein loading buffer (Bio-Rad) containing 2 mM biotin and 20 mM DTT at 95 °C for 10 min and subjected to 4–15% SDS-PAGE followed by Western blot analysis described below.

**Western blot analysis.** For Western blots of affinity purified biotinylated proteins by Mito-APEX, we followed previously described procedures.16 The following primary antibodies were used: IP3R antibody (PA1-901, Thermo Scientific, rabbit polyclonal, 1:1000), GFP antibody (sc-8334, Santa Cruz Biotechnology, rabbit polyclonal, 1:500), and GAPDH antibody (CB1001, Calbiochem, mouse monoclonal, 1:5000). For Western blots of RlucC-ER and Mito-RlucC, HEK293T cells were transfected with split-Rluc constructs as described above.
Cells treated with DMSO, isoproterenol, actinomycin, or isoproterenol/actinomycin for 1 h were lysed and subjected to 4–15% SDS-PAGE followed by Western blotting as described before. Primary antibodies against MYC (2276, 9E10, Cell signaling, mouse monoclonal, 1:1000), FLAG (F1804, M2, Sigma, mouse monoclonal, 1:1000), and actin (1844–1, Epitomics, rabbit monoclonal, 1:2000), and the appropriate secondary antibodies were used. For protein half-life analysis, HEK293T cells were treated with actinomycin D and cycloheximide together and harvested at different time points as indicated.

**Calcium level measurement.** To monitor the mitochondrial and cytoplasmic calcium dynamics, mito-R-GECO1 and GCaMP6s constructs respectively were transfected into HeLa cells in an 8-well chamber slide. Sixteen hours after transfection, the cells were treated with DMSO or indicated drugs and imaged on Zeiss Observer Z1 inverted microscope using Zeiss Zen Pro software, every 2.5 or 5 s. Approximately 7.5 s (histamine) or 15 s (ionomycin) after the start of the experiment, histamine (100 μM) or ionomycin (3 μM) was superfused over transfected cells. The boundary of each cell was set as ROIs (regions of interest) and randomly selected based on the presence of R-GECO1 or GCaMP6s fluorescent signal. ∆F/F₀ and (∆F/F₀)/∆t (R-GECO1) (from 7.5 to 12.5 s) were calculated as described previously.

**Mitochondrial transmembrane potential and mitochondrial length.** Mitochondrial membrane potential (Ψₘₐ) was measured by tetramethyl rhodamine methyl ester (TMRM) fluorescent dye (I34361, Thermo Fisher Scientific). HeLa cells were loaded with 10 nM TMRM for 30 min at RT and then treated with DMSO or isoproterenol (1 μM) for 1 h. TMRM fluorescence was imaged using Zeiss Observer Z1 inverted microscope, and the signal intensity was analyzed in Image J. The lengths of mitochondria were analyzed in Image Analyst MKII software (version 4.0) with default parameter [largest mitochondria size (width in pixel) = 5, Sensitivity (top range scaling, percentile) = 99.5 and minimum size (area, pixels) = 5].

**GPCR expression level analysis using mRNA-seq data.** The raw sequence files were downloaded from NIH GEO data sets with each GEO set access number (GSE99249 for HEK293T, GSE122986;SRR8247560 for HeLa, GSE148617;SRR10125054 for C2C12, GSE84481;SRR9327979 for Neuro2a). The downloaded fastq files were aligned and sorted with GRCh38 or GRCm38 genome index by HISAT2 (version 2.1.0) and samtools (version 1.9), respectively. We calculated TPM with TPMCalculator.

**Statistical analysis.** All statistical analyses were performed using GraphPad Prism (version 8.4.2 or 9.1.0) or R (version 4.0.0). To determine whether differences between two data sets are statistically significant, a two-tailed t-test was used if the data passed normality test; a non-parametric test (Mann Whitney test) was used if failed normality test. When more than two data sets were compared, a 1- or 2-way ANOVA test was used if passed normality test; other tests recommended by Prism software (e.g., Kruskal–Wallis test) were used if data failed the normality test. For comparisons of multiple samples following these tests, Dunn's test, Dunnett's test, or Sidak's test was used as recommended by Prism. For data normality analysis, Anderson–Darling, D'Agostino–Pearson, Shapiro–Wilk, and Kolmogorov–Smirnov tests were used. For the categorical data comparison, a Chi-square test was used. The details of all statistical tests including the exact p-values and sample numbers (n) are listed in the figure legends or directly in the graphs. All samples (e.g., cells, mitochondria, and ROIs etc.) were randomly selected, and image quantifications were carried out blindly. P values ≤ 0.05 were considered statistically significant. When fold changes were used, all data were normalized to control (e.g., DMSO). All bar graphs are plotted as mean ± standard deviation (SD). Concentration responsive curves are plotted as mean ± SEM. All scattered plots are marked with individual data points and median with inter quartile range.

Received: 14 July 2021; Accepted: 7 October 2021
Published online: 02 November 2021

**References**

1. Coordás, G., Weaver, D. & Hajnóczky, G. Endoplasmic reticulum-mitochondrial contactology: Structure and signaling functions. *Trends Cell. Biol.* 28(7), 523–540 (2018).
2. Kornmann, B. et al. An ER-mitochondria tethering complex revealed by a synthetic biology screen. *Science* 325(5939), 477–481 (2009).
3. Eisenberg-Bord, M., Shai, N., Schuldiner, M. & Bohnert, M. A tether is a tether is a tether: Tethering at membrane contact sites. *Dev. Cell* 39(4), 395–409 (2016).
4. Paillusson, S. et al. There’s something wrong with my MAM; the ER-mitochondria axis and neurodegenerative diseases. *Trends Neurosci.* 39(3), 146–157 (2016).
5. Molteno, O., Remondelli, P. & Amadio, G. The mitochondria-endoplasmic reticulum contacts and their critical role in aging and age-associated diseases. *Front. Cell. Dev. Biol.* 7, 172 (2019).
6. Rieusset, J. The role of endoplasmic reticulum-mitochondria contact sites in the control of glucose homeostasis: An update. *Cell Death Dis.* 9(3), 388 (2018).
7. Drogman Bouguerra, M. & Lalli, E. ER-mitochondria interactions: Both strength and weakness within cancer cells. *Biochim. Biophys. Acta Mol. Cell. Res.* 1866(4), 630–662 (2019).
8. Lim, Y., Cho, I.-T., Schoel, L. J., Cho, G. & Golden, I. A. Hereditary spastic paraplegia-linked REEP1 modulates endoplasmic reticulum/mitochondria contacts. *Annu. Neurol.* 78(5), 679–696 (2015).
9. Tepkin, A. V. Mitochondrial junctions with cellular organelles: Ca²⁺ signalling perspective. *Pflugers Arch. – Eur. J. Physiol.* 470(8), 1181–1192 (2018).
21. Cárdenas, C.
20. Bravo, R.
22. Territo, P. R., Mootha, V. K., French, S. A. & Balaban, R. S. Ca(2+) activation of heart mitochondrial oxidative phosphorylation:
12. Weis, W. I. & Kobilka, B. K. The molecular basis of G protein-coupled receptor activation.
15. Gronich, N.
13. Inoue, A.
16. Cho, I.-T.
29. Chakrabarti, R.
32. Ji, W.-K.
30. Plenge-Tellechea, F., Soler, F. & Fernandez-Belda, F. On the inhibition mechanism of sarcoplasmic or endoplasmic reticulum
33. Shao, X., Li, Q., Mogilner, A., Bershadsky, A. D. & Shivashankar, G. V. Mechanical stimulation induces formin-dependent assembly
31. Kuschak, M.
35. Sinha, S. & Yang, W. Cellular signaling for activation of Rho GTPase Cdc42.
37. van Unen, J.
38. Jin, M.
42. Bartok, A.
41. Giordano, F.
40. Wang, Y.
43. Taylor, C. W. & Tovey, S. C. IP(3) receptors: Toward understanding their activation.
48. Murga, C., Laguinge, L., Wetzker, R., Cuadrado, A. & Gutkind, J. S. Activation of Akt/protein kinase B by G protein-coupled
47. Barazzuol, L., Giamogante, F., Brini, M. & Calì, T. PINK1/parkin mediated mitophagy, Ca2+ signalling, and ER-mitochondria
51. Boyle, E. I. et al. GO::TermFinder–open source software for accessing Gene Ontology information and finding significantly enriched
50. López De Jesús, M. et al. Cyclic AMP-dependent and Epac-mediated activation of R-Ras by G protein-coupled receptors leads to
283
217
216
215
214
213
212
211
210
209
208
207
206
205
204
203
202
201
200
199
198
197
196
195
194
193
192
191
190
189
188
187
186
185
184
183
182
181
180
179
178
177
176
175
174
173
172
171
170
169
168
167
166
165
164
163
162
161
160
159
158
157
156
155
154
153
152
151
150
149
148
147
146
145
144
143
142
141
140
139
138
137
136
135
134
133
132
131
130
129
128
127
126
125
124
123
122
121
120
119
118
117
116
115
114
113
112
111
110
109
108
107
106
105
104
103
102
101
100
99
98
97
96
95
94
93
92
91
90
89
88
87
86
85
84
83
82
81
80
79
78
77
76
75
74
73
72
71
70
69
68
67
66
65
64
63
62
61
60
59
58
57
56
55
54
53
52
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
55. Vera Alvarez, R., Pongor, L. S., Mariño-Ramírez, L. & Landsman, D. TPMCalculator: One-step software to quantify mRNA abundance of genomic features. Bioinformatics 35(11), 1960–1962 (2019).

Acknowledgements
This work was supported by NINDS (R01NS100007) and by Dana-Farber Cancer Institute microgrant (#120205). The authors are grateful to Dr Jeffrey A. Golden and his lab members (BWH/HMS) for their support and critical review of the manuscript, to Dr Sandro Santagata (BWH/HMS) for a critical review of the manuscript, to Drs Sean E. Lawler and Michal Oscar Nowicki (BWH/HMS) for sharing their reagents and equipment, to Amanda Frischmann for her assistance on compound list curating process, and to Dr Wei Wang (BWH/HMS) for her help with statistical analyses supported by the Harvard Catalyst/The Harvard Clinical and Translational Science Center (NIH award UL 1TR002541). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the NIH.

Author contributions
Y.L. and G.C. designed the study. Y.L., I.-T. C., H.G.R., and G.C. conducted experiments. Y.L. and G.C. analyzed the data, prepared figures and wrote the manuscript. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-00801-w.

Correspondence and requests for materials should be addressed to G.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021